Compare Marvell Technology Inc (MRVL) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Smith & Nephew plc — how do they compare? Marvell Technology Inc trades at $271.75 (market cap $246.84B), while Smith & Nephew plc trades at $27.08 (market cap $11.10B). The key difference: Marvell Technology Inc is far larger — about 22.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Smith & Nephew plc for 120 Days on average.
| MRVL | SNN | |
|---|---|---|
Market Cap | $246.84B | $11.10B |
Volume | 29,003,830 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $316.43 | $37.17 |
52-Week Low | $73.73 | $26.42 |
Typical Hold Time | 42 Days | 120 Days |
Enterprise Value | $248.19B | $14.13B |
Dividend Yield | 0.09% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $271.49, down 4.63% today but maintains strong momentum with 210% year-to-date gains. The stock shows bullish technical signals with support at $267 and resistance at $282. Fundamentally, MRVL reported three consecutive earnings beats and projects explosive growth, with fiscal 2028 revenue guidance raised to $18 billion. Analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $327.86 consensus target.
MRVL presents compelling growth prospects driven by AI chip demand and hyperscaler partnerships, particularly the $120 billion Google deal. However, elevated valuation multiples (P/E 90.95, P/S 25.77) and recent net losses (-$885M in 2025) warrant caution. The stock's 210% surge this year increases volatility risk, though strong institutional support and custom silicon expansion provide long-term upside potential.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
